BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today highlighted its recent pipeline ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback